Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab

NCT06172036 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

180

Enrollment

OTHER

Sponsor class

Conditions

Neoadjuvant Chemotherapy
Resectable Pancreatic Cancer

Interventions

DRUG: irinotecan liposome + oxaliplatin + 5-FU / LV
DRUG: Adebellizumab

Sponsor

Zhejiang University